Equities

Carna Biosciences Inc

4572:TYO

Carna Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)398.00
  • Today's Change10.00 / 2.58%
  • Shares traded58.90k
  • 1 Year change-50.99%
  • Beta1.8599
Data delayed at least 20 minutes, as of May 31 2024 07:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Carna Biosciences, Inc. is a Japan-based company mainly engaged in the drug development support business and the drug development business. The Company operates in two business segments. The Drug Development Support segment is engaged in sales of protein kinase, development of assay, as well as provision of profiling and screening service. The Drug Development segment is engaged in the research and development of kinase inhibitors and other drugs.

  • Revenue in JPY (TTM)1.58bn
  • Net income in JPY-1.03bn
  • Incorporated2003
  • Employees67.00
  • Location
    Carna Biosciences IncKIBC Bldg. 5115-5-2 Minatojima-MinamimachiChuo-kuKOBE-SHI 650-0047JapanJPN
  • Phone+81 783027039
  • Fax+81 783026665
  • Websitehttps://www.carnabio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Solasia Pharma KK408.00m-1.18bn5.42bn24.00--2.80--13.28-6.96-6.962.4010.010.14322.013.0617,000,000.00-41.50-48.57-53.67-58.8351.2371.01-289.71-300.891.68-400.000.2327---43.5014.1856.36------
Noile-Immune Biotech Inc311.30m-975.80m5.67bn28.00--1.06--18.22-22.56-22.567.19123.550.06580.1395.0711,118,000.00-20.62---21.29--99.55---313.45--52.74-805.650.00---49.37---192.28------
Cyfuse Biomedical KK64.79m-645.40m6.05bn21.00--1.97--93.37-82.27-82.278.26378.390.01530.520213.803,085,095.00-15.19---17.68--61.81---996.19--6.39-81.610.2126---83.68---24.32------
DNA Chip Research Inc490.46m-248.29m6.17bn36.00--8.42--12.58-39.09-39.0977.17108.270.52929.843.11---26.79-23.49-32.60-26.7013.5314.28-50.62-54.102.92-2,206.97----49.746.3331.48---15.75--
NIPPON CHEMIPHAR CO., LTD.30.75bn-180.00m6.67bn872.00--0.30595.700.2169-49.89-49.898,520.205,115.780.62682.142.70---0.36890.7482-0.52041.0825.1730.99-0.58871.131.53--0.479150.33-2.57-2.10-153.10--24.62-12.94
Chiome Bioscience Inc642.70m-1.30bn6.71bn51.00--5.31--10.44-25.56-25.5612.6022.390.33484.278.9612,602,040.00-67.53-50.50-88.83-57.3855.9657.53-201.70-224.743.46-629.880.2009--8.1926.241.84------
Symbio Pharmaceuticals Ltd4.64bn-2.74bn7.07bn109.00--0.9848--1.52-66.88-66.88113.80156.380.54392.765.1442,594,130.00-32.15-19.18-35.33-23.6278.3865.84-59.12-24.3210.43--0.00---44.157.82-266.45--42.39--
MEDRx Co Ltd22.57m-770.66m7.08bn22.00--3.37--313.46-20.97-20.970.612847.840.01430.004.221,025,955.00-48.80-58.15-50.27-62.23100.0095.70-3,414.38-1,526.1743.57--0.00---50.3528.6016.04---55.29--
Carna Biosciences, Inc.1.58bn-1.03bn7.19bn67.00--1.94--4.55-60.32-60.3292.24205.190.35741.2412.6323,578,990.00-23.36-14.45-25.26-16.9589.0390.59-65.36-35.4213.18--0.0326--17.2416.5914.57---27.69--
Veritas In Silico Inc-100.00bn-100.00bn7.47bn15.00--3.17----------363.52------------------------40.94--0.00--101.54--123.38------
K Pharma Inc500.00m-221.98m8.20bn15.00--2.86--16.41-18.94-18.9443.04247.430.20954.49--33,333,330.00-9.30---9.83--91.00---44.40--42.60--0.00------166.34------
TMS Co Ltd0.00-960.04m8.46bn14.00--2.45-----25.89-25.890.0085.770.00----0.00-26.14---26.78-------------2,219.420.00-------11.51------
CellSeed Inc193.68m-892.21m8.54bn35.00--4.00--44.12-29.71-29.716.4764.750.0881.637.625,533,600.00-40.53-49.69-43.83-54.5556.5863.66-460.67-428.6219.14--0.0669--50.39-28.62-11.43--80.73--
Wakamoto Pharmaceutical Co Ltd7.74bn108.96m8.85bn292.0080.910.73390.511.143.143.14222.97346.510.49712.092.57--0.70-2.280.8046-2.6446.5251.001.41-3.973.85--0.0083---10.65-6.35-21.19--4.93--
Tsubota Laboratory Inc673.53m-641.32m9.08bn10.00--6.64--13.48-25.15-25.1526.4253.450.27112.0437.74---25.82---36.41--3.17---95.22--2.31-489.860.0788---29.45---811.14------
Kohjin Bio Co Ltd4.77bn384.98m9.08bn157.0023.152.6722.281.9076.7776.77951.17666.48----------------39.44--8.07--1.14--0.4249--0.5715---53.61------
Data as of May 31 2024. Currency figures normalised to Carna Biosciences Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

7.66%Per cent of shares held by top holders
HolderShares% Held
Athos Capital Ltd.as of 31 May 2024900.00k5.25%
PineBridge Investments Japan Co., Ltd.as of 31 Dec 2023281.90k1.64%
Simplex Asset Management Co., Ltd.as of 09 May 202467.50k0.39%
SSgA Funds Management, Inc.as of 09 May 202448.60k0.28%
Mitsubishi UFJ Asset Management Co., Ltd.as of 27 Feb 202313.40k0.08%
LGT Capital Partners AG (Investment Management)as of 31 May 20231.60k0.01%
D�m Finance SASas of 30 Jun 2023400.000.00%
Connor, Clark & Lunn Investment Management Ltd.as of 31 Dec 2023200.000.00%
More ▼
Data from 30 Jun 2023 - 24 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.